Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF – Get Free Report)’s share price traded up 0.9% during trading on Monday. The company traded as high as $16.7730 and last traded at $16.45. Approximately 554 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 8,608 shares. The stock had previously closed at $16.30.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group lowered Kyowa Kirin to a “hold” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce”.
Check Out Our Latest Stock Analysis on Kyowa Kirin
Kyowa Kirin Stock Performance
The stock’s fifty day simple moving average is $15.21 and its 200-day simple moving average is $14.63.
About Kyowa Kirin
Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical company and a member of the Kirin Holdings group. The company researches, develops, manufactures and markets prescription medicines, with an emphasis on specialty therapies for conditions that often have significant unmet medical needs. Its focus areas include oncology, immunology, nephrology, neurology and rare diseases. Kyowa Kirin’s products include Crysvita (burosumab), a treatment for certain phosphate-wasting disorders, and Poteligeo (mogamulizumab), an antibody therapy used for specific blood cancers.
See Also
- Five stocks we like better than Kyowa Kirin
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.
